Analyst Daily

Polaris Inc. (NYSE:PII), Hikma Pharmaceuticals PLC (LSE:HIK) Following the Levels

Polaris Inc. (NYSE:PII) has a Q.i. Value of 32.00000. The Q.i. Value ranks companies using four ratios. These ratios consist of EBITDA Yield, FCF Yield, Liquidity, and Earnings Yield. The purpose of the Q.i. Value is to help identify companies that are the most undervalued. Typically, the lower the value, the more undervalued the company tends to be.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Investors may be intent on creating unique strategies when approaching the equity markets. Individuals with longer-term mindsets may have completely different strategies than those who trade in the short-term. Whatever class they fall under, investors may have to decide how aggressive they want to be in order to capitalize on these strategies. Navigating the bull market may make things a bit easier for some and much harder for others. Many investors will set their sights on dips and corrections. This may prove to be a successful strategy, but this may also create many missed opportunities. Keeping track of key economic data along with market trends and earnings information typically seems to be a boon to any strategy. Highly active traders may keep close watch after the markets have a sleepy session or two. Investors staying the course might actually be relieved when activity cools a bit.

Checking in on some valuation rankings, Polaris Inc. (NYSE:PII) has a Value Composite score of 39. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 31.

Watching some historical volatility numbers on shares of Polaris Inc. (NYSE:PII), we can see that the 12 month volatility is presently 42.046500. The 6 month volatility is 40.579900, and the 3 month is spotted at 37.178900. Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period.

Polaris Inc. (NYSE:PII) has a current ERP5 Rank of 4522. The ERP5 Rank may assist investors with spotting companies that are undervalued. This ranking uses four ratios. These ratios are Earnings Yield, ROIC, Price to Book, and 5 year average ROIC. When looking at the ERP5 ranking, it is generally considered the lower the value, the better.

We can now take a quick look at some historical stock price index data. Polaris Inc. (NYSE:PII) presently has a 10 month price index of 1.20318. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period. Looking at some alternate time periods, the 12 month price index is 1.06264, the 24 month is 0.82258, and the 36 month is 1.22783. Narrowing in a bit closer, the 5 month price index is 1.10501, the 3 month is 1.27366, and the 1 month is currently 0.99257.

Return on Assets

There are many different tools to determine whether a company is profitable or not. One of the most popular ratios is the “Return on Assets” (aka ROA). This score indicates how profitable a company is relative to its total assets. The Return on Assets for Polaris Inc. (NYSE:PII) is 0.076302. This number is calculated by dividing net income after tax by the company’s total assets. A company that manages their assets well will have a higher return, while a company that manages their assets poorly will have a lower return.

Return on Invested Capital (ROIC), ROIC Quality, ROIC 5 Year Average

The Return on Invested Capital (aka ROIC) for Polaris Inc. (NYSE:PII) is 0.333536. The Return on Invested Capital is a ratio that determines whether a company is profitable or not. It tells investors how well a company is turning their capital into profits. The ROIC is calculated by dividing the net operating profit (or EBIT) by the employed capital. The employed capital is calculated by subrating current liabilities from total assets. Similarly, the Return on Invested Capital Quality ratio is a tool in evaluating the quality of a company’s ROIC over the course of five years. The ROIC Quality of Polaris Inc. (NYSE:PII) is 2.278893. This is calculated by dividing the five year average ROIC by the Standard Deviation of the 5 year ROIC. The ROIC 5 year average is calculated using the five year average EBIT, five year average (net working capital and net fixed assets). The ROIC 5 year average of Polaris Inc. (NYSE:PII) is 0.506008.

FCF Yield 5yr Avg

The FCF Yield 5yr Average is calculated by taking the five year average free cash flow of a company, and dividing it by the current enterprise value. Enterprise Value is calculated by taking the market capitalization plus debt, minority interest and preferred shares, minus total cash and cash equivalents. The average FCF of a company is determined by looking at the cash generated by operations of the company. The Free Cash Flow Yield 5 Year Average of Polaris Inc. (NYSE:PII) is 0.037737.

Gross Margin score

Investors may be interested in viewing the Gross Margin score on shares of Polaris Inc. (NYSE:PII). The name currently has a score of 36.00000. This score is derived from the Gross Margin (Marx) stability and growth over the previous eight years. The Gross Margin score lands on a scale from 1 to 100 where a score of 1 would be considered positive, and a score of 100 would be seen as negative.

With most major indexes showing strength, it is safe to assume that many investors may have their heads in the clouds. With many stocks frequently hitting new milestone highs, investors may be scrambling to make sure that they aren’t missing out on possible returns. Maybe some stocks have been doing well, but others not in the portfolio have been doing much better. There is rarely any substitute for hard work and dedication. Investors may get complacent with stocks that they are familiar with. Branching out into uncharted waters may help broaden the horizon and start the gears grinding for new trading ideas. Traders and investors will no doubt be closely monitoring the markets as we move into the second half of the year. It remains to be seen whether optimism or pessimism will rule going in to the next round of quarterly earnings reporting.

The Q.i. Value ranks companies using four ratios. These ratios consist of EBITDA Yield, FCF Yield, Liquidity, and Earnings Yield. The purpose of the Q.i. Value is to help identify companies that are the most undervalued. Typically, the lower the value, the more undervalued the company tends to be. Hikma Pharmaceuticals PLC (LSE:HIK) currently has a Q.i. Value of 23.00000.

Coming up with a viable and solid stock investment plan might be on the minds of many individual investors. A solid plan might entail defining the overall objective and recognizing tangible restraints. Figuring out these details may help the investor focus on the most important aspects of investing in the stock market. Following strategies set forth by others may work, but they may also leave the investor in a quandary. What worked in the past for one person may not work in the future for another. Investors may need to craft the plan keeping in mind the long-term goals. Although some investors and traders focus on the short-term, many investors are more interested in making the grade over a number of years, and not a number of days or months. Plans may need to be set up so that they are flexible and have the ability to withstand unforeseen shifts and rapidly changing stock market scenarios. Flexibility may end up being the key to a successful plan down the road. Investors may also want to do regular check-ins on portfolio performance in order to keep tabs on how well the plan is working.

We can now take a quick look at some historical stock price index data. Hikma Pharmaceuticals PLC (LSE:HIK) presently has a 10 month price index of 1.31831. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period.

Looking at some alternate time periods, the 12 month price index is 1.11527, the 24 month is 1.92640, and the 36 month is 1.21980. Narrowing in a bit closer, the 5 month price index is 1.14491, the 3 month is 0.96886, and the 1 month is currently 0.97610.

Hikma Pharmaceuticals PLC (LSE:HIK) has a current ERP5 Rank of 3545. The ERP5 Rank may assist investors with spotting companies that are undervalued. This ranking uses four ratios. These ratios are Earnings Yield, ROIC, Price to Book, and 5 year average ROIC. When looking at the ERP5 ranking, it is generally considered the lower the value, the better.

Checking in on some valuation rankings, Hikma Pharmaceuticals PLC (LSE:HIK) has a Value Composite score of 44. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. These ratios are price to earnings, price to cash flow, EBITDA to EV, price to book value, and price to sales. The VC is displayed as a number between 1 and 100. In general, a company with a score closer to 0 would be seen as undervalued, and a score closer to 100 would indicate an overvalued company. Adding a sixth ratio, shareholder yield, we can view the Value Composite 2 score which is currently sitting at 42.

Watching some historical volatility numbers on shares of Hikma Pharmaceuticals PLC (LSE:HIK), we can see that the 12 month volatility is presently 29.393900. The 6 month volatility is 24.544000, and the 3 month is spotted at 22.586600. Following volatility data can help measure how much the stock price has fluctuated over the specified time period. Although past volatility action may help project future stock volatility, it may also be vastly different when taking into account other factors that may be driving price action during the measured time period.

Current Ratio

The Current Ratio of Hikma Pharmaceuticals PLC (LSE:HIK) is 1.28. The Current Ratio is used by investors to determine whether a company can pay short term and long term debts. The current ratio looks at all the liquid and non-liquid assets compared to the company’s total current liabilities. A high current ratio indicates that the company might have trouble managing their working capital. A low current ratio (when the current liabilities are higher than the current assets) indicates that the company may have trouble paying their short term obligations.

Gross Margin Score

The Gross Margin Score is calculated by looking at the Gross Margin and the overall stability of the company over the course of 8 years. The score is a number between one and one hundred (1 being best and 100 being the worst). The Gross Margin Score of Hikma Pharmaceuticals PLC (LSE:HIK) is 23.00000. The more stable the company, the lower the score. If a company is less stable over the course of time, they will have a higher score.

M-Score (Beneish)

The M-Score, conceived by accounting professor Messod Beneish, is a model for detecting whether a company has manipulated their earnings numbers or not. Hikma Pharmaceuticals PLC (LSE:HIK) has an M-Score of -2.426135. The M-Score is based on 8 different variables: Days’ sales in receivables index, Gross Margin Index, Asset Quality Index, Sales Growth Index, Depreciation Index, Sales, General and Administrative expenses Index, Leverage Index and Total Accruals to Total Assets. A score higher than -1.78 is an indicator that the company might be manipulating their numbers.

Piotroski F-Score

The Piotroski F-Score is a scoring system between 1-9 that determines a firm’s financial strength. The score helps determine if a company’s stock is valuable or not. The Piotroski F-Score of Hikma Pharmaceuticals PLC (LSE:HIK) is 6. A score of nine indicates a high value stock, while a score of one indicates a low value stock. The score is calculated by the return on assets (ROA), Cash flow return on assets (CFROA), change in return of assets, and quality of earnings. It is also calculated by a change in gearing or leverage, liquidity, and change in shares in issue. The score is also determined by change in gross margin and change in asset turnover.

Stock market investing can sometimes cause investors heads to spin. Following stocks on a daily basis, it is plain to see the amount of coverage that follows certain companies. This non-stop barrage of information may eventually become overwhelming for the novice investor. Filtering through all the data may involve taking a look at a company or stock from multiple angles. There are many investors out there that preach strictly following fundamental data. There are others that swear by the technical analysis. Many investors will opt to employ a research strategy that involves pieces of the two approaches. Knowing every little detail about a company may not be overly necessary, but it may help provide a bit more direction when navigating the stock market maze. Investors who put in the time to study all the fundamentals may want to also start watching the charts on stock that they are thinking about adding to the portfolio. Making sure that no stone is left unturned when examining a stock may end up being the difference between a big winner and a big loser.

Leave a Reply

Your email address will not be published. Required fields are marked *